• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Highlights of India’s first Biotech startup Expo
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid
  • Moderna and Pfizer: Lawsuits and Charitable Giving
  • European Commission Approves Two GM Crops for Food and Feed
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»Quick Exit of FDA Commissioner Dr Scott Gottlieb

Quick Exit of FDA Commissioner Dr Scott Gottlieb

0
By Biotech Express on March 6, 2019 Articles, Articles- Editorials

FDA is the world’s largest healthcare agency of USA and is responsible for the development of Science all over the world. It is imperative by the fact that simply a rejection of manufacturing Unit of a company can lead to severe loss on stock exchanges all over the world.

But here we are discussing about the quick exit of FDA Chief Dr Scott Gottlieb(46) which is a reaction of several actions that he took and more to some personal reasons here which he think is the priority for him at this time.

According to latest reports by Time, CNN, Fortunately he is finally resigning from the post and seen as a good sign for the hounded growth of Tobacco industry.
Dr. Scott Gottlieb said in a letter to staff Tuesday that he will be leaving the agency.

“It’s is hard for me to write this note to share with you the news that I’ll be leaving my job as the Commissioner of Food and Drugs in the next month. There’s perhaps nothing that could pull me away from this role other than the challenge of being apart from my family for these past two years and missing my wife and three young children,” says the letter, which the FDA tweeted.

Dr Gottlieb is facing serious difficulty after his move on banning cigarettes even to replace them by e-cigarettes and Teen vaping. As head of the FDA, Gottlieb made crack down on e-cigarettes and vaping as a key part of his tenure. During his tenure as commissioner, Gottlieb approved a record number of treatments and drugs and advanced policies to confront opioid addiction and prevent youth e-cigarette use. He also faced the longest government shutdown in history. He has been particularly aggressive on the issue of e-cigarette use, targeting convenience stores that sell vaping products, aiming to limit the access and appeal these products have for children.

Move of Dr Gottlieb can affect many industries in the market, specially the pharmaceutical and medical device business. The one category is Biologics and biosimilars which he developed a lot in his regime. According to many he has approved record biosimilars in the market, and that is why the biologics drug manufacturers are looking forward curiously for the coming administration.

Alex Azar, secretary of the Department of Health and Human Services, the FDA’s parent agency, said in a statement Tuesday that Gottlieb “has been an exemplary public health leader, aggressive advocate for American patients, and passionate promoter of innovation.”

USA President Donald Trump also tweeted about Gottlieb’s planned departure, saying he’s done a “absolutely terrific job.”

“Scott has helped us to lower drug prices, get a record number of generic drugs approved and onto the market, and so many other things. He and his talents will be greatly missed!”

Dr Gottlieb previously worked as a senior adviser to the Centers for Medicare and Medicaid Services and was appointed by the Senate to serve on the Federal Health Information Technology Policy Committee.
Before these appointments, he served as a clinical assistant professor at the New York University School of Medicine in Manhattan, where he also practiced medicine as a hospitalist physician.

He completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University in Connecticut, where he studied economics.

Dr Gottlieb is also a cancer survivor, a venture capitalist and a government insider who long said he wanted to tear down the wall of FDA regulations that he believes is holding back innovation.

Not everyone is praising Dr Gottlieb’s tenure. The advocacy group Public Citizen said in a statement Tuesday that his time as the agency’s head “was marked by regulatory decision making regarding medications and medical devices that tilted further in favor of industry’s financial interests rather than the interests of public health.”

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible?

Letter: Public Health Bill to be presented in the Monsoon session 2022 is Illegal, Unconstitutional and Arbitrary: Dr Maya Valecha

Paid publishing in science has killed peer review system, says CSIR’s ex-chief Shekhar Mande

Leave A Reply Cancel Reply

Current Issue – May 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
  • Moderna and Pfizer: Lawsuits and Charitable Giving May 25, 2022
  • European Commission Approves Two GM Crops for Food and Feed May 25, 2022
  • Ayush Ministry, DBT sign MoU for cooperation on evidence-based biotech interventions in Ayush sector May 24, 2022
  • CCI, India merger approved absorption of Covidshield Technologies into Biocon Biologics May 20, 2022
  • No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible? May 19, 2022
  • Industry lobbying on WHO overshadowing public health policy, researchers suggest May 18, 2022
  • Letter: Public Health Bill to be presented in the Monsoon session 2022 is Illegal, Unconstitutional and Arbitrary: Dr Maya Valecha May 15, 2022
  • Paid publishing in science has killed peer review system, says CSIR’s ex-chief Shekhar Mande May 15, 2022
  • Bill Gates tests positive for COVID-19 even after many booster doses, mocked on twitter May 10, 2022
  • Another Ivermectin COVID-19 paper retracted May 8, 2022
  • COVID-19 spike protein paper retracted May 7, 2022
  • Killer Music? Can sound make a clot in a boy who died while dancing or it is related to COVID vaccination May 7, 2022
  • Clotting Risks Cause FDA to Restrict Use of J&J COVID Vaccine May 6, 2022
  • Department of Pharmaceuticals releases “Common Guidelines on Pharmaceutical Innovation and Entrepreneurship” for academic institutions May 6, 2022
  • No medical care for 45% of recorded deaths in 2020, highest ever in India: New data May 6, 2022
  • Indian opposition seeks higher compensation for COVID deaths after damning WHO report May 6, 2022
  • Redcliffe Lifetech raises $61 million in Series B funding May 6, 2022
  • Engineers Create an Enzyme That Breaks Down Plastic Waste in Hours, Not Decades May 5, 2022
  • Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr May 5, 2022
  • The Union Government has Lied to the Supreme Court in COVID Vaccines Case? May 5, 2022
  • COVID-19- vitamin D paper from India retracted by Springer Nature journal May 4, 2022
  • IISc develops 3D printed gloves for rehabilitating stroke patients May 4, 2022
  • A new wearable technology — for plants May 4, 2022
  • Sanofi India names Rodolfo Hrosz managing director effective June 1 May 4, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.